ReviewCancers2018
Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05754788 (Identification of Gene Expression Profile Associated With Favorable Prognosis in Patients Undergoing Radical Surgery for Pancreatic and Ampullary Adenocarcinoma), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Identification of Gene Expression Profile Associated With Favorable Prognosis in Patients Undergoing Radical Surgery for Pancreatic and Ampullary Adenocarcinoma
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- The mechanisms and clinical prospects of combining chemotherapy with immunotherapy for advanced pancreatic cancer.Discover oncology · 2026Review
- Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer.Developmental cell · 2025Article
- Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study).ESMO gastrointestinal oncology · 2025Article
- Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas.International journal of molecular sciences · 2024Article
- The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.International journal of molecular sciences · 2024Review
- Current and future immunotherapeutic approaches in pancreatic cancer treatment.Journal of hematology & oncology · 2024Review
- Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer.bioRxiv : the preprint server for biology · 2024Article
- Establishment of a reference single-cell RNA sequencing dataset for human pancreatic adenocarcinoma.iScience · 2022Article
- Review
- Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer.Cancers · 2022Review
- Individualized prognostic signature for pancreatic carcinoma validated by integrating immune-related gene pairs (IRGPs).Bioengineered · 2021Article
- Review
- Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report.Frontiers in oncology · 2021Article
- Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification.Journal of clinical medicine · 2020Review
- Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications.Journal of experimental & clinical cancer research : CR · 2020Review
- Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.The Lancet. Oncology · 2020Review
- Identification of prognostic risk factors for pancreatic cancer using bioinformatics analysis.PeerJ · 2020Article
- Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.The oncologist · 2019Article
- Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features.British journal of cancer · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) continues to be a disease with poor outcomes and short-lived treatment responses. New information is emerging from genome sequencing identifying potential subgroups based on somatic and germline mutations. A variety of different mutations and mutational signatures have been identified; the driver mutation in around 93% of PDAC is
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.